ERBB2 and breast carcinoma: HER2-driven up-regulation of FASN protein expression in luminal B-like MCF-7/HER2-18 breast cancer cells, however, remained largely unresponsive to the regulatory effects of estradiol and/or tamoxifen (Figure 2A).